Behind the Niche Movers: DexCom's OTC Push and aTyr's Biotech OverhaulGlobal Report·Aug 11 at 04:43 AMATYR+5.68%PCG+2.90%
ATYR Pharma | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0Earnings Watch·Aug 7 at 03:16 PMATYR+5.68%
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q SummaryTradingView·Aug 7 at 03:11 PMATYR+5.68%
aTyr Pharma submits Phase 3 efzofitimod trial protocol to FDA for pulmonary sarcoidosis studyPUBT·Aug 7 at 03:08 PMATYR+5.68%
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILDUnusual Whales·Aug 7 at 03:05 PMATYR+5.68%
The Island of Misfit Stocks: Who Is Actually Making Money?Global Report·Jul 28 at 04:13 AMJPM-D+0.61%TT-0.10%
From Labor Markets to the AI Fringe: A Cross-Section of the 2026 EconomyGlobal Report·Jul 24 at 04:13 AMATYR+5.68%AMPGR0.00%
aTyr Pharma submits FDA protocol for planned Phase 3 efzofitimod sarcoidosis studyPUBT·Jul 15 at 07:02 AMATYR+5.68%
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026Unusual Whales·Jul 15 at 07:02 AMATYR+5.68%
ATYR: Efzofitimod advances toward approval with a new phase III trial targeting restrictive sarcoidosisQuartr·Jun 25 at 03:55 PMATYR+5.68%
